<code id='E951EE3248'></code><style id='E951EE3248'></style>
    • <acronym id='E951EE3248'></acronym>
      <center id='E951EE3248'><center id='E951EE3248'><tfoot id='E951EE3248'></tfoot></center><abbr id='E951EE3248'><dir id='E951EE3248'><tfoot id='E951EE3248'></tfoot><noframes id='E951EE3248'>

    • <optgroup id='E951EE3248'><strike id='E951EE3248'><sup id='E951EE3248'></sup></strike><code id='E951EE3248'></code></optgroup>
        1. <b id='E951EE3248'><label id='E951EE3248'><select id='E951EE3248'><dt id='E951EE3248'><span id='E951EE3248'></span></dt></select></label></b><u id='E951EE3248'></u>
          <i id='E951EE3248'><strike id='E951EE3248'><tt id='E951EE3248'><pre id='E951EE3248'></pre></tt></strike></i>

          Home / knowledge / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:2

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In